Join Ultima at Booth #504
Join Ultima Genomics at ESHG 2026, where we will be showcasing our recently launched UG200 Series of high-throughput sequencers. Coupled with Solaris 2.0 chemistry, the UG200 enables up to 20B reads per wafer, with flexibility down to 5B per wafer to meet your project needs.
Ultima is delivering the power, speed, and resolution researchers need to unlock the next breakthroughs in genomics research, and support applications such as whole-genome sequencing, part-per-million SNV detection for minimal residual disease (MRD), and large-scale, single-cell projects on millions of cells and beyond.
Join our session: Redefining High-Throughput Sequencing
Session CS41: Redefining High-Throughput Sequencing
- Time: 10:30 AM - 11:30 AM CEST
- Speakers:
-
Alex Watkins Staff Field Applications Scientist Ultima Genomics Talk title: An Introduction to Ultima Sequencing -
Dr. Peter Bauer Chief Medical and Genomic Officer Centogene Talk title: Evaluation of Ultima Genomics technology for rare disease diagnostics -
Dr. Melissa Miller Senior Director of Human Genetics, Internal Medicine Research Unit Pfizer Talk title: Building the World’s Largest Proteogenomics Resource: A New Foundation for Human Biology
-
- Location: Room A-6
This scientific session explores how Ultima sequencing technology and large‑scale genomic resources are reshaping discovery in human biology and medicine. The session opens with an overview of Ultima Genomics, introducing the UG200™‑series platform and Solaris 2.0 sequencing chemistry, and outlining how this technology supports scalable workflows across whole‑genome sequencing, single‑cell analysis, and other emerging applications.
Dr. Peter Bauer (Centogene) will present an evaluation of Ultima Genomics technology in a clinical research setting focused on rare disease diagnostics. Using cases with known pathogenic variants, Dr. Bauer’s team assessed genome coverage, read length, variant concordance, as well as clinical utility on the UG 100® platform.
The session concludes with Dr. Melissa Miller (Pfizer), who will discuss how large-scale proteomics data, when integrated with genetic and clinical phenotype information, provides a powerful framework for uncovering novel biology. This presentation will describe the UK Biobank Pharma Proteomics Project, which will constitute the largest proteogenomic resource to date.
Posters
Poster: P20.169.A
Date: Saturday, June 13 l Time: 12:15 - 13:15 l Session: Group A
Evaluation of Ultima Genomics genome sequencing in rare disease diagnostic settings
Presenting Author: Krishnakumar Kandaswampy, CTO, Centogene
Meet our team at ESHG
REQUEST A MEETING